You are here

Article Text

Article menu
Download PDFPDF
Letter
Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus
  1. M D de Kruif1,2,
  2. M Limper1,2,
  3. H R Hansen1,2,
  4. J de Ruiter1,
  5. C A Spek2,
  6. E C M van Gorp1,
  7. I J ten Berge3,
  8. A T Rowshani3,
  9. H ten Cate4,
  10. E W Meesters1
  1. 1
    Department of Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands
  2. 2
    Centre for Experimental and Molecular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
  3. 3
    Department of Internal Medicine, Division of Nephrology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
  4. 4
    Laboratory for Clinical Thrombosis and Haemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, Maastricht, The Netherlands
  1. Correspondence to Dr M D de Kruif, Department of Internal Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; m.d.dekruif{at}amc.uva.nl

https://doi.org/10.1136/ard.2009.109405

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Systemic lupus erythematosus (SLE) is associated with a highly increased cardiovascular risk. Statins can reduce this risk, but may possess additional anti-inflammatory effects that are relevant for the treatment of SLE. In a preliminary study, we investigated the effects of a 3-month course of rosuvastatin on lipids and markers of inflammation using a randomised cross-over design.

    The study was approved by the institutional medical and ethical committee and written informed consent was obtained from all subjects. Based upon a previous, representative study,1 a sample size of 14 patients would be necessary to demonstrate a 25% reduction in C-reactive protein (CRP) levels (power = 80%). A dropout level of 35% (n = 5) was estimated.2 Patients with stable …

    View Full Text

    Footnotes

    • Funding This study was supported by an unrestricted research grant to HtC from AstraZeneca, The Netherlands.

    • Competing interests None.

    • Provenance and Peer review Not commissioned; externally peer reviewed.

    • Ethics approval Approval from the medical and ethical committee of the Slotervaart Hospital and Jan van Breemen Institute (located at the Slotervaart Hospital), Amsterdam.